Abstract
A major goal in clinical pharmacology is the quantitative prediction of drug effects. The field of pharmacokinetic–pharmacodynamic (PK/PD) modelling has made many advances from the basic concept of the dose–response relationship to extended mechanism-based models. The purpose of this article is to review, from a historical perspective, the progression of the modelling of the concentration–response relationship from the first classic models developed in the mid-1960s to some of the more sophisticated current approaches. The emphasis is on general models describing key PD relationships, such as: simple models relating drug dose or concentration in plasma to effect, biophase distribution models and in particular effect compartment models, models for indirect mechanism of action that involve primarily the modulation of endogenous factors, models for cell trafficking and transduction systems. We show the evolution of tolerance and time-variant models, non- and semi-parametric models, and briefly discuss population PK/PD modelling, together with some example of more recent and complex pharmacodynamic models for control system and nonlinear HIV-1 dynamics. We also discuss some future possible directions for PK/PD modelling, report equations for general classes of novel semi-parametric models, as well as describing two new classes, additive or set-point, of regulatory, additive feedback models in their direct and indirect action variants
Similar content being viewed by others
References
Mager D., Wyska E., Jusko W. (2003). Diversity of mechanism-based pharmacodynamic models. Am. Soc. Pharmacol. Exp. Therapeut. 31:510–519
Tallarida R.J. (1984). Receptor theories and quantitative effect versus dose–concentration relationship. Drug Metab. Rev. 15:345–363
Verotta D., Sheiner L.B. (1995). A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J. Pharmacokin. Biopharm. 23:1–4
Dayneka N., Garg V., Jusko W. (1993). Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457–478
Levy G. (1994). Mechanism-based pharmacodynamic modeling. Clin. Pharmacol. Therapeut. 56:356–358
Verotta D. (1996). Concepts, properties, and applications of linear systems to describe the distribution, identify input, and control endogenous substances and drugs in biological systems. CRC Crit. Rev. Biomol. Eng. 24:73–139
D. Verotta. Semi-parametric direct and indirect action models for pharmacokinetics/pharmacodynamic data. In: Proceedings Society Computer Simulation Western Multiconference, Las Vegas, Nevada, USA, 1995.
Segre G. (1968). Kinetics of interaction between drugs and biological system. Il Farmaco Ed. Sci. 23:907–918
Levy G. (1966). Kinetics of pharmacologic effects. Clin Pharm Therapeut. 7:362–372
Levy G. (1964). Relationship between elimination rate of drugs and rate of decline of their pharmacological effect. J. Pharm. Sci. 53:343–343
Levy G., Nelson E. (1965). Theoretical relationship between dose, elimination rate, and duration of pharmacologic effect of drugs. J. Pharm. Sci. 54:812
Levy G. (1965). Apparent potentiating effect of a second dose of drug. Nature 206:517–519
Wagner J. (1968). Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J. Theoret. Biol. 20:173–201
Ariens E. (1964). The mode of action of biologically active compounds. In: De Stevens G (eds). Molecular Pharmacology. Academic Press, New York
Black J.W., Leff P. (1983). Operational models of pharmacological agonism. Proc. R. Soc. Lond. B. 220:141–162
Tuk B., Van Oostenbruggen M., Herben V.M.M. et al. (1999). Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: Midazolam and ∝-OH-midazolam. J. Pharmacol. Exp. Therapeut. 289:1067–1074
Van der Graaf P., Van Schaick E., Mathot R. et al. (1997). Mechanism-based pharmacokinetic–pharmacodynamic modeling of the effects of N 6-cyclopentylasenosine analogs on heart rate in rat: Estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J. Pharmacol. Exp. Therapeut. 283:809–816
Furchgott R. (1955). The pharmacology of vascular smooth muscle. Pharm. Res. 7:183–265
Ferguson J. (1939). The use of chemical potentials as indices of toxicity. Proc. Roy. Soc. London, s.B. 127:387–404
Berman M., M.F. Weiss. SAAM manual. U.S. Department of Health, Education and Welfare, Public Health Service Publication No. 1703. Washington, DC, U.S. Government Printing Office, 200 pp. 1967.
Boston C., Greif P.C., Berman M. (1981). Conversational SAAM—An interactive program for kinetic analysis of biological systems. Comput. Programs Biomed. 1981: 111–119
SAAM. In Series. Seattle, WA: SAAM Institute, Inc. http://www.saam.com/software/saam2/saam2software.htm.
Dahlstrom B., Paalzow L., Segre G. et al. (1978). Relation between morphine pharmacokinetics and Analgesia. J. Pharmacokinet. Biopharm. 6:41–53
Levy G., Gibaldi M., Jusko W. (1969). Multicompartment pharmacokinetic models and pharmacologic effects. J. Pharm. Sci. 58:422–424
Galeazzi R., Benet L., Sheiner L. (1976). Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin. Pharmacol. Ther. 20:278–289
Kramer W., Kolibash A., Lewis R. et al. (1979). Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man. J. Pharmacokinet. Biopharm. 7:47–61
Mandema J., Veng-Pedersen P., Danhof M. (1991). Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions. J. Pharmacokinet. Biopharm. 19:617–634
Sheiner L., Stanski D., Vozeh S. et al. (1979). Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358–371
Jusko W. (1971). Pharmacodynamics of chemotherapeutic effects: Dose–time–response relationships for phase-non-specific agents. J. Pharm. Sci. 60:892–895
Jusko W. (1973). A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. J. Pharmacokinet. Biopharm. 1:175–200
Nagashima R., O’Reilly R., Levy G. (1969). Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin. Clin. Pharmacol. Ther. 10:22–35
Sheiner L. (1969). Computer-aided long-term anticoagulation therapy. Comput. Biomed. Res. 2:507–518
Theophanus T., Barile R. (1973). Multiple-dose kinetics of oral anticoagulants: Methods of analysis and optimised dosing. J. Pharm. Sci. 62:261–266
Abbrecht P. O’Leary T., Behrendt D. (1982). Evaluation of a computer-assisted method for individualized anticoagulation: Retrospective an prospective studies with a pharmacodynamic model. Clin. Pharmacol. Ther. 32: 129–136
O’Leary T., Abbrecht P. (1981). Predicting oral anticoagulant response using a pharmacodynamic model. Ann. Biomed. Eng. 9: 199–216
Sharma A. (1998). Precursor-dependant indirect pharmacodynamic response model for tolerance and rebound phenomena. J. Pharm. Sci. 87:1577–1584
Earp J., Krzyzanski W., Chakraborty A. et al. (2004). Assessment of drug interactions relevant to pharmacodynamic indirect response models. J. Pharmacokine. Pharmacodynam. 31:345–380
Wald J. (1991). Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J. Pharmacokinet. Biopharm. 19:521–536
Kong A., Ludwig E., Slaughter R. et al. (1989). Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin. Pharmacol. Therpeut. 46:616–628
Dunn T., Ludwig E., Slaughter R. et al. (1991). Pharmacokinetics and pharmacodynamics of methylprednisolone in obese and on-obese men. Clin. Pharmacol. Therpeut. 50:536–549
Frey B., Walker C., Frey F. et al. (1984). Pharmacokinetics of three different prednisolone produrgs: effect on circulating lymphocyte subsets and function. J. Immunol. 133: 2479–2487
Munck A., Leung K. (1977). Glucocorticoid receptors and mechanisms of action of steroid hormones Receptors and Mechanisms of Action of Steroid Hormones. Marcel Dekker, New York pp. 311–397
Evans R. (1988). The steroid and thyroid hormone receptor superfamily. Science 240: 889–895
Boudinot F., D’Ambrosio R., Jusko W. (1986). Receptor-mediated pharmacodynamics of prednisolone in the rat. J. Pharmacokinet. Biopharm. 14: 469–493
Nichols A. (1989). Second generation model for prednisolone pharmacodynamics in the rat. J. Pharmacokinet. Biopharm. 17:209–227
Sun Y., Jusko W. (1998). Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J. Pharm. Sci. 87:732–737
Oosterhuis B., Braat M., Roos C. et al. (1986). Pharmacokinetic–pharmacodynamic modeling of terbutaline bronchodilation in asthma. Clin. Pharmacol. Therpeut 40:469–475
Mager D., Jusko W. (2001). Pharmacodynamic modeling of time-dependent transduction systems. Clin. Pharmacol. Therpeut. 70:210–216
Lobo E., Balthasar J. (2002). Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro. AAPS Pharmaceut. Sci. 4:1–11
Zahler R., Wachter P., Jatlow P. et al. (1982). Kinetics of drug effect by distributed lags analysis: An application to cocaine. Clin. Pharmacol. Therpeut. 31:775–782
Ekbad E., Licko V. (1984). A model eliciting transient responses. Am. J. Physiol. 246:R114–R121
Chow M., Ambre J., Ruo T. et al. (1985). Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin. Pharmacol. Therpeutic. 38:318–324
Hammarlund M., Odling B., Paalzow L. (1985). Acute tolerance to furosemide diuresis in humans. Pharmacokinetic–Pharmacodynamic modelling. J. Pharmacol. Exp. Therpeut. 233:447–453
Porchet H., Benowitz N., Sheiner L. (1988). Pharmacodynamic model of tolerance: Application to nicotine. J. Pharmacol. Exp. Therpeut. 244:231
Shi J., Benowitz N., Denaro C. et al. (1993). Pharmacokinetic–pharmacodynamic modeling of caffeine: Tolerance to pressor effects. Clin. Pharmacol. Therpeut. 53:6–14
Mandema J.W., Wada D. (1995). Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J. Pharmacol. Exp. Therpeut. 279:1035–1042
Shafer S.L., Siegel L.C., Cooke J.E. et al. (1988). Testing computer-controlled infusion pumps by simulation. Anesthesiology 68:261–266
Shafer S.L., Gregg K.M. (1992). Algorithms to rapidly achieve and maintain stable drug concentrations at the site of drug effect with a computer controlled infusion pump. J. Pharmacokinet Biopharm. 20:147–169
Verotta D. (1999). A general solution for non-parametric control of a linear system using computer controlled infusion pumps. IEEE Trans. Biomed. Eng. 46:44–50
Bauer J., Balthasar J., Fung H. (1997). Application of pharmacodynamic modeling for designing time variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure. Pharm. Res. 14:114–145
Francheteau P., Steimer J., Dubray C. et al. (1991). Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: Application to the prolactin suppressant effect of the dopaminomimetic drug DCN203–922. J. Pharmacokinet. Biopharm. 19:287–309
Lew K., Ludwig E., Milad M. et al. (1993). Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynmamics. Clin. Pharmacol. Therpeut. 54: 402–414
Gries J., Benowitz N., Verotta D. (1996). Chronopharmacokinetics of nicotine. Clin. Pharmacol. Therpeut. 60:385–395
Hull C., Van Beem H., and McLeod K. et al. (1978). A pharmacodynamic model for pancuronium. Brit. J. Anaesth 50:1113–1123
Fuseau E. and Sheiner L. (1984). Simultaneous modeling of pharmacokinetic and pharmacodynamics with a nonparametric model. Clin. Pharmacol. Therpeut. 35:733–741
Unadkat J., Bartha F., and Sheiner L. (1986). Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric and dynamic models. Clin. Pharmacol. Therpeut. 40:86–93
Verotta D. and Sheiner L. (1987). Simultaneous modeling of pharmacokinetics and pharmacodynamics: An improved algorithm. Comput. Appl. Biostat 3:345–349
Verotta D., Beal S., and Sheiner L. (1989). Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am. J. Physiol. 256:R1005–R1010
Verotta D. (1989). An inequality-constrained least-squares deconvolution method. J. Pharmacokinet. Biopharm. 17:269–289
Veng-Pedersen P., Mandema J., and Danhof M. (1991). A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. J. Pharm. Sci. 80:488–495
Tuk B., Danhof M., and Mandema J. (1997). The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. J. Pharmacokinet. Biopharm. 25:39–60
Tuk B., Herben V., and Mandema J. et al. (1998). Relevance of arteriovenous concentration differences in pharmacokinetic–pharmacodynamic modeling of midazolam. J.Pharmacol. Exp. Therpeut. 284:202–207
Verotta D. and Sheiner L.B. (1991). Semiparametric analysis of non-steady-state pharmacodynamic data. J. Pharmacokin. Biopharm 19:691–712
Troconiz I.F., Sheiner L.B. and Verotta D. (1994). Semiparametric models for drug interactions. J. Appl. Physiol 76:2224–2233
Holford N. (1990). Concepts and usefulness of pharmacokinetic–pharmacodynamic modeling. Fundament. Clin. Pharmacol. Therapeut 4:93–101
Rowland M. (1985). Variability in Drug Therapy–Description, Estimation and Control. Raven Press Boks Ltd, New York
Sheiner L., Rosenberg B., and Melmon K. (1972). Modeling of individual pharmacokinetics for computer-aided drug dosage. Comput. Biomed. Res. 5:441–459
Beal S. and Sheiner L.B. NONMEM I Users Guide. Technical Report, Division of Clinical Pharmacology, University of California at San Francisco, 1984.
Yuh L., Beal S. and Davidian M. et al. (1994). Population pharmacokinetic/pharmacodynamic methodology and applications: A bibliography. Biometrics 50:566–575
Sheiner L. and Ludden T. (1992). Population pharmacokinetics/dynamics. Annu. Rev. Pharmacol. Toxicol. 32:185–209
Sheiner L. and Beal S. (1982). Bayesian individualisation of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci. 71:1344–1348
Minto C. (1998). Expanding clinical applications of population pharmacodynamic modeling. Brit. J. Clin. Pharmaco 46:321–333
Boeckmann A.J., Beal S.L., and Sheiner L.B. NONMEM V Users Guides. Technical Report, Division of Clinical Pharmacology, University of California at San Francisco, 1998.
WinNonmix® Pharsight. http://www.pharsight.com/products/winnonmix/index.php.
D. D’Argenio and A. Schumitzky. ADAPT II User’s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. In Series ADAPT II User’s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles, 1997.
PopKinetics. SI, INC. http://www.saam.com/software/popKinetics/popKineticsSoftware.htm.
PKBUGS. MRC Biostatistics Unit, Cambridge, UK. http://www.mrc-bsu.cam.ac. uk/bugs/winbugs/pkbugs.shtml.
Fattinger K., Verotta D., and Porchet H. et al. (1996). Modelling a bivariate control system: LH and testosterone response to the GnRH antagonist Antide. Am. J. Physiol. 271: E775–E787
Zuideveld K., Maas H., and Treijtel N. et al. (2001). A set-point model with oscillatory behaviour predicts the time course of (8-)-OH-DPAT induced hypothermia. Am. J. Physiol. 281: R2059–R2071
Bridges N.A., Hindsmarsh P.C., and Pringle P.J. et al. (1993). The relationship between endogenous testosterone and gonadotropin secretion. Clin. Endocrinol 38:373–378
Bonhoeffer S., May R.M. and Shaw G.M. et al. (1997). Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA. 94:6971–6976
Nowak M.A. and May R.M. (1991). Mathematical biology of HIV infections: Antigenetic variation and diversity threshold. Math. Biosci. 106:1–21
Nowak M.A., Bonhoeffer S., and Shaw G.M. et al. (1997). Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell population. J. Theoret. Biol. 184:203–217
Wein L.M., DAmato R.M., and Perelson A.S. (1998). Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J. Theoret. Biol 192: 81–98
Stafford M.A., Corey L., and Cao Y. et al. (2000). Modelling plasma virus concentration during primary HIV infection. J. Theoret. Biol. 203: 285–301
Y. Huang and L. Wu. Mechanistic PK/PD modeling of antiretroviral therapies in AIDS clinical trials. In Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, Vol. III. Kluwer Academic Publishers, Boston, 2004, pp. 221–238.
Nowak M.A. and May R.M. (1992). Coexistence and competition in HIV infections. J. Theoret. Biol. 159:329–342
Perelson A.S. and Essunger P. (1997). Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 387:188–191
Perelson A.S., Neumann A.U., and Markowitz M. et al. (1996). HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582–1587
Wu H. and Ding A.A. (1999). Population HIV-1 dynamics in vivo: Applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 55:410–418
Ding A.A. and Wu H. (2000). A comparison study of models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies. Biometrics 56:293–300
Verotta D. and Schaedeli F. (2002). Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials. Math. Biosci. 176: 163–183
May R.M. (1987). Nonlinearity and complex behavior in simple ecological and epidemiological models. Perspect. Biol. Dynam. Theoret. Med 504:1–15
D. Verotta. Models and estimation methods for clinical HIV-1 data. J. Comput. Appl. Math., in press.
Efron B. and Feldman D. (1991). Compliance as an explanatory variable in clinical trial. J. Am. Stat.Assoc 86:9–17
Urquhart J. and De Klerk E. (1998). Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat. Med. 17:251–267; discussion 387–259
Homer. Iliad, Book XIII; c. 850 BC.
C. M. Metzler. A user’s manual for NONLIN. The Upjohn Co. Techn. Rep. 7292/69/7292/005. Kalama 700. Mich., 1969.
Gelman A., Carlin J.B., and Stern H. et al. (1995). Bayesian Data Analysis. Chapman & Hall, London
Distefano-III J.J. and Landaw E.M. Multiexponential, multicompartmental, and noncompartmental modeling. I. Methodological limitations and physiological interpretations. Am. J. Physiol. Regulat. Integrat. Comp. Physiol. 15(1984).
Verotta D. (2003). Volterra series in pharmacokinetics and pharmacodynamic. J. Pharmacokinet. Pharmacodynam 30:337–362
Volterra V. (1959). Theory of Functionals and of integral and Integro-Differential Equations. Dover, New York
Marmarelis V.Z. (1993). Identification of nonlinear biological systems using laguerre expansions of kernels. Ann. Biomed. Eng. 21:573–589
C. DeBoor.A Practical Guide to Splines, 1978.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Csajka, C., Verotta, D. Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives. J Pharmacokinet Pharmacodyn 33, 227–279 (2006). https://doi.org/10.1007/s10928-005-9002-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-005-9002-0